SAB Biotherapeutics Warrant
SABSW
9 hedge funds and large institutions have $93K invested in SAB Biotherapeutics Warrant in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
5% more capital invested
Capital invested by funds: $88.4K → $93K (+$4.65K)
0.83% more ownership
Funds ownership: 1.68% → 2.51% (+0.83%)
10% less funds holding
Funds holding: 10 → 9 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$42.8K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$313 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
-$10 |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$10 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LP
1
LMR Partners
London,
United Kingdom
| $37.8K | – | – | – |
|
|
SCM
2
Shaolin Capital Management
Miami,
Florida
| $33K | +$42.8K | +465,717 | New |
|
3
Morgan Stanley
New York
| $10.4K | – | – | – |
|
|
YCM
4
Yakira Capital Management
Westport,
Connecticut
| $8.14K | – | – | – |
|
5
Walleye Capital
New York
| $1.63K | – | – | – |
|
6
Walleye Trading
New York
| $1.08K | – | – | – |
|
|
WAM
7
Wolverine Asset Management
Chicago,
Illinois
| $893 | +$313 | +3,400 | +36% |
|
|
NA
8
NewEdge Advisors
New Orleans,
Louisiana
| $75 | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $4 | – | – | – |
|
|
CS
10
Clear Street
New York
| – | -$10 | -100 | Closed |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$10 | -100 | Closed |
|
SABSW Hedge Fund Activity: Q3 2023 in Review
9 of the 6,303 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q3 2023, worth a combined $93K — up 5.3% from $88.4K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SABSW and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Shaolin Capital Management, opening a new position worth an estimated $42.8K. The largest seller was Clear Street, exiting entirely with an estimated $10 sold.
- 9 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q3 2023, down from 10 in Q2 2023.
- Funds reported $93K of SAB Biotherapeutics Warrant stock for Q3 2023, up 5.3% quarter-over-quarter.
- 1 fund opened new SAB Biotherapeutics Warrant positions in Q3 2023 and 2 closed out, a net change of -1 holder.
- The largest SAB Biotherapeutics Warrant buyer in Q3 2023 was Shaolin Capital Management, an estimated $42.8K added.
- The largest SAB Biotherapeutics Warrant seller in Q3 2023 was Clear Street, an estimated $10 sold.
Based on aggregated 13F filings for Q3 2023.